Related Experiment Videos
[Health security--GMOs in therapeutics].
1Agence française de Sécurité sanitaire des Produits de Santé, 143 Bd A. France, F93285 Saint-Denis.
Annales Pharmaceutiques Francaises
|April 2, 2003
Summary
Genetically modified organisms (GMOs) advance human therapeutics by producing high-quality therapeutic proteins and gene therapy vectors. Rigorous risk assessment ensures safe and effective GMO applications in medicine.
Area of Science:
- Molecular biology
- Biotechnology
- Genetic engineering
Context:
- Advances in human therapeutics rely on molecular biology for producing human-like proteins.
- Genetically modified organisms (GMOs) are crucial for manufacturing high-value therapeutic proteins with satisfactory quality.
Purpose:
- To explore the role and safety of GMOs in producing therapeutic proteins and as gene therapy vectors.
- To address the risks associated with GMO use in medicine, including contamination, neo-antigenicity, and environmental concerns.
Summary:
- GMOs enable the production of therapeutic proteins identical to human proteins in sequence and structure.
- GMOs can serve as vectors for direct administration in gene therapy.
- Potential risks such as microbiological contamination, neo-antigenicity, and environmental impact are carefully managed.
Impact:
- Biotechnology-derived medicines have significantly advanced therapeutic options.
- Careful risk management ensures a favorable benefit/risk ratio for GMO-based therapeutics.
- The use of GMOs in medicine maintains a high standard of health security.